Novo Nordisk entered into a definitive agreement to acquire Akero Therapeutics, Inc., a publicly held clinical-stage company developing treatments for serious metabolic diseases, for $4.7 billion in cash at closing with a contingent value right of $500 million. Akero’s fibroblast growth factor 21 (FGF21) analogue efruxifermin (EFX) is a potentially best-in-class treatment for metabolic dysfunction-associated steatohepatitis (MASH). EFX is currently in phase 3 development for the treatment of ...